The Harvard motor neurone disease drug developer secured the return of Amgen Ventures for its series A round.

Quralis, a US-based neurological disease medicine spinout of Harvard University, has raised $42m of series A funding from investors including Amgen Ventures, the corporate venturing arm of pharmaceutical firm Amgen Ventures. UK government-backed investment unit Dementia Discovery Fund co-led the round together with LS Polaris Innovation Fund, Mission BioCapital, Inkef Capital and Droia Ventures. The…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.